Kardigan, Inc.
KARDNasdaq
$21.13
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↓ -4.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our principal executive offices are located in Princeton, NJ.
- CEO
- Tassos Gianakakos
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 241
- Headquarters
- California
- Website
- www.kardigan.bio
Management & directors
- Edelberg JayChief Medical Officer
- Gianakakos AnastasiosPresident & CEO
- Jahn BrianneChief Financial Officer
- Moriarty John BChief Legal Officer
- Pasternak AndyChief Strategy Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | SCHF (GPE), LLC | Buy | 3,125,000 | $16.00 | $50.0M | filing |
| 2026-06-22 | BERNS PAUL L | Buy | 1,250,000 | $16.00 | $20.0M | filing |
| 2026-06-22 | ARCH Venture Partners XIII, LLC | Buy | 1,250,000 | $16.00 | $20.0M | filing |
| 2026-06-17 | Edelberg Jay· Chief Medical Officer | Award | 47,784 | $0.00 | $0.00 | filing |
| 2026-06-17 | PERCEPTIVE ADVISORS LLC | Award | 20,706 | $0.00 | $0.00 | filing |
| 2026-06-17 | Pasternak Andy· Chief Strategy Officer | Award | 79,640 | $0.00 | $0.00 | filing |
| 2026-06-17 | Meeker David P | Award | 20,706 | $0.00 | $0.00 | filing |
| 2026-06-17 | BERNS PAUL L | Award | 20,706 | $0.00 | $0.00 | filing |
| 2026-06-17 | Moriarty John B· Chief Legal Officer | Award | 47,784 | $0.00 | $0.00 | filing |
| 2026-06-17 | Jahn Brianne· Chief Financial Officer | Award | 79,640 | $0.00 | $0.00 | filing |
| 2026-06-17 | Popovits Kimberly J | Award | 20,706 | $0.00 | $0.00 | filing |
| 2026-06-17 | Walbert Timothy P | Award | 20,706 | $0.00 | $0.00 | filing |
| 2026-06-17 | Giordano Douglas E. | Award | 20,706 | $0.00 | $0.00 | filing |
| 2026-06-17 | GIANAKAKOS ANASTASIOS· President & CEO | C | 41,001 | — | — | filing |
| 2026-06-17 | GIANAKAKOS ANASTASIOS· President & CEO | C | 498,692 | — | — | filing |
| 2026-06-17 | SCHF (GPE), LLC | C | 6,150,502 | — | — | filing |
| 2026-06-17 | SCHF (GPE), LLC | C | 3,242,993 | — | — | filing |
| 2026-06-17 | SCHF (GPE), LLC | C | 2,348,373 | — | — | filing |
| 2026-06-17 | ARCH Venture Partners XIII, LLC | C | 13,792,035 | — | — | filing |
| 2026-06-17 | SCHF (GPE), LLC | C | 2,050,166 | — | — | filing |
| 2026-06-17 | Edelberg Jay· Chief Medical Officer | C | 97,587 | — | — | filing |
| 2026-06-17 | BERNS PAUL L | C | 13,792,035 | — | — | filing |
| 2026-06-17 | GIANAKAKOS ANASTASIOS· President & CEO | C | 28,702 | — | — | filing |
Latest 23 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.